for how you, Matt. start Aziyo. Today, earnings the with for XXXX highlights. our overview fit lastly, context strategy questions. Ferguson, into your recent wrap to quarter of describe for first I’ll Thank our our up I’ll and the Welcome open And overall with an After results. I our will we call. efforts Matt then the moving CFO, provide forward. for will financial line details that, priorities the will company
We in. have so ground let’s jump to a cover, of lot
exceptional businesses. miss for was and the be growth hard our First, delivered were businesses. across record all XX% to a by Sales the quarter, seen to of this line four our it would up performance financial $XX.X million top
to process starting year-over-year Recall, of in and last half the some to XX%. made Erica changes attributed that made our led her margin of the saw margin, improvements substantial we by improvement And was impressive efforts of we in really the team year. one results. leadership second her are Erica XX gross Furthermore, to is in team, The Elchin. up by operations improvement gross points largely a produce
fivefold. XX-person LeMaitre’s which LeMaitre a coverage With gained with to surgeon, this made business development front, partnership Vascular we cardiovascular dedicated of creating to on team progress expert included to access the increasing deal, cardiovascular portfolio. distribute our up, needs sales Next we great the approximately the
increase a of coverage Sientra’s surgery in access current Like with the sales These greatly the for footprint SimpliDerm. partnership and time, Sientra, our professionals, increase partnership and LeMaitre, outcome a distribution manner. product transactions addition improve now are reconstruction they breast operationalizing this leader we a to for Similarly, with SimpliDerm XX commercial at expands our patient same nonexclusive with best-in-class our again, fivefold enable sales approximately our us coverage. in over capital-efficient
Lastly, FDA. we’ve made with progress
of for agency CanGaroo our NSE for receipt FDA. were Devices productive, limited product to being XXX(k). of a animal of results regulated the or we The for generation both data. teams the the RM’s RM, request importantly, granted review the a vitro with the at CanGaroo Center RM requested additional Following does by letter clear not was in is quality meeting The a CanGaroo understanding as information with for the the testing require of the any human and Center and the from is combination as meeting resubmission Drugs control
R&D this agency on provide the and be generating confident we to are laser-focused Our able with information are will information. teams required the
of system there you CanGaroo and a or also an each infection, complications surgical mortality their and are fibrosis, surgical that SimpliDerm the experience. very better and this into require for procedures medical between Now over movement, the is practical arise they or re-intervention regenerative patient the mention $X.X a Complications not patient interface the very that so believe year, strategy device interface, We and or the at overall Aziyo, look it That’s our address, essential Aziyo. it that erosion, mission at whether cost to that improving morbidity and let’s real patient massive is to patient context treat. intended family of application medically When the put medicine is for severe of to billion. XX,XXX just the the represents humanize device strong performance that problem outcomes. and health it’s enormous care the our be that devices At from opportunity.
really exciting. Now what think is is we here
protein delivery highly pouch bound, elution. than can also technology rather that therapeutically because The effect the that many saw this challenge material to these simple our And still longer create developing elution dramatically synergistic pathogenic biologically-based at the get We’re ability them biologic effects. a of a the much keeping proven that’s the we there combination preclinical drug combines And are drug-eluting active Weeks has drugs the after of bacteria. in RM. biologic. for two and CanGaroo of benefits site produce with to X-log was you studies relevant drug so are with would kill complete, therapeutic the
So iceberg. with relatively antibiotics therapeutics we’re but just RM, we simple starting here, tip that’s like the think really with of CanGaroo the
focused business our businesses. markets which implantation to So work now this is let’s served. according SimpliDerm, into today, technology different which porcine-derived an technology, lastly, the primarily reconstruction. putting cardiac pacemaker it but These breast units to also Cardiovascular, are look at used used surgery; spine orthopedics is is allograft envelope has then business dermis and indications technology leverages our in which neurostimulation how and in our we’re surgery. matrix and with like. Aziyo for extracellular four acellular vascular organized across CanGaroo, on that’s orthobiologics, the and
believe technology and and our we continue high-growth for CanGaroo forward. moving are SimpliDerm be businesses that Our opportunities best are drug product They leverage will us. to eluting two lines also
the is Focusing partner, proprietary the distribute margin channels. saw great There a top through very Scientific. other CanGaroo a are that and benefit minute, a without subcutaneous force supplementation. Boston we placement, on we antibiotic a the efficacy. gross CanGaroo some real has for our been is with One fibrosis particularly and migration two healthy improvements. tremendous work defibrillator has of shows distribution that to clinical is line threat through published both in where through product sales This and value, CanGaroo, and
it. There of demonstrating College is this a Look effect. JACC, Cardiology, new of the for out Journal in paper the American
exciting being some have New Orleans. upcoming also We Society data Rhythm at presented Annual Heart Meeting in the
May from booth to there be XX XX at XXX. will We the
product the We CanGaroo on currently minocycline. high-quality without will that to If you there, this and in antibiotics. see we now version that can everyone of love resubmission is wants again, of can we would elutes of you. tell a But will CanGaroo opening, our are know, antibiotics to confident filed the stop are rifampin be you as produce to RM, the all that calendar activity when be marketed is great submission. for the resubmit by. to And it the question two, know we preparing I is What our within we ready mentioned pouch And year. FDA? I
we will gain more updates as specificity. provide further We
to moving SimpliDerm. Now
SimpliDerm breast breast of of implant added Here, we XX%. love product. sell as dermal Surgeons We have distributor this acellular frequently an Sientra, of sense own our as network. use we requires partner. line through growth a saw manufacturer, both product. And top lot organizations surgery the implant announced, recently makes a as And this for
to see line these We also increase saw of an and very we the process from the partnership, is in volume Sientra improvements reduction improvements, SimpliDerm, of SimpliDerm in on with resulting this gross on us, important substantially. believe nice expect for Cost profitability we increase along increases manufacturing. goal goods will margin with a
of On but a the this the terms solid organization. have house, we still other revenue we saw cardiovascular in the of yet, here, side our and growth producers These businesses growth more orthobiologics for cash potential, which great And businesses. are even our quarter. are mature
new the and business current reps is in In with adding at our about transfer to model, sales XX in that partnership open approximately to new cardiovascular we’re our direct Our of this XX%, was market. half LeMaitre sell bulk our will up recognizing coverage. product what a up significantly, LeMaitre we product price representation end
approximately XX% we estimate that a Therefore, strategic on realize and with this should higher be we other that, our of despite and volumes profitability our flow. Now as we what no will expect our forward, that with partnership margin will improve cash again, gross going selling cost. virtually much moves,
orthobiologics. terms is under made new here, Our progress It is final revenue. our in we’ve business remarkable And unit leadership. largest of
driven sales we for These period, are has and by the along by demand margin improvements the team million, think to likely the improvements to way, are gross which both improved of process continue. XX grew For and points. implemented product strong $X.X the X%
in very strong a all, all quarter. So
turn financial stop to talking to Matt With that, some highlights. it us over and give I’ll
